糖皮质激素减量速度对增殖性狼疮肾炎肾脏结局的影响:一项多中心回顾性研究
本研究为多中心回顾性病历回顾,纳入344例初治、经活检证实的增殖性狼疮肾炎患者,比较6个月内将泼尼松等效剂量减至≤7.5 mg/天的快速减量组(50例)与未达此速度的常规减量组(294例)。12个月部分肾脏缓解率快速组43/50(86%)对比常规组248/294(84.4%),校正混杂因素后无显著差异(校正风险比0.92,P=0.758),2年随访复发率与严重不良事件两组相当。
要点
- 12个月部分肾脏缓解率快速减量组43/50(86%)与常规减量组248/294(84.4%)相近。
- 校正年龄、基线UPCR、基线eGFR、合并膜性病变、初始GC剂量、甲泼尼龙冲击、强效免疫抑制剂及羟氯喹后,校正风险比0.92(P=0.758)。
- 2年随访期内两组复发率与严重不良事件相当。
核心结论
- 在增殖性狼疮肾炎患者中,6个月内将糖皮质激素快速减至≤7.5 mg/天未损害肾脏结局,也未增加复发。
研究设计与样本
- 多中心回顾性病历回顾,共纳入17个中心的344例初治、经活检证实的增殖性狼疮肾炎患者,均有治疗前及治疗后52周尿蛋白/肌酐比值(UPCR)数据。
- 快速减量组为6个月内将泼尼松等效剂量减至≤7.5 mg/天的患者(50例),常规减量组为未达此速度者(294例)。
- 采用改良泊松回归分析校正混杂因素。
主要发现
- 12个月部分肾脏缓解率:快速减量组43/50(86%),常规减量组248/294(84.4%)。
- 校正年龄、基线UPCR、基线估算肾小球滤过率、肾小球合并膜性病变、初始GC剂量、甲泼尼龙冲击治疗、强效免疫抑制剂(吗替麦考酚酯、环磷酰胺或利妥昔单抗)及羟氯喹后,12个月部分肾脏缓解无显著差异(校正风险比0.92,P=0.758)。
- 2年随访期内两组复发率与严重不良事件相当。
关键数值与推荐
- 快速减量定义:6个月内泼尼松等效剂量减至≤7.5 mg/天。
- 主要结局:12个月部分肾脏缓解(PRR)。
临床怎么用
- 原文结论为6个月内快速减至≤7.5 mg/天未损害肾脏结局、未增加复发;原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Recent guidelines and recommendations for LN suggest rapid glucocorticoid (GC) reduction; however, robust supporting evidence remains limited. This study aimed to evaluate the impact of rapid GC reduction on renal outcomes in patients with proliferative LN. METHODS: We conducted a multicentre retrospective chart review of patients with GC-naïve, biopsy-proven proliferative LN with available urinary protein-to-creatinine ratio (UPCR) data before and 52 weeks after GC treatment. Patients who reduced their prednisolone-equivalent dose to ≤7.5 mg/day within 6 months (rapid GC reducers) were compared with those who did not (conventional GC reducers) regarding partial renal response (PRR) at 12 months. Modified Poisson regression analysis was used to adjust for confounding factors. RESULTS: A total of 344 patients from 17 centres were included: 50 rapid GC reducers and 294 conventional GC reducers. PRR at 12 months was achieved by 43/50 (86%) in the rapid GC group and 248/294 (84.4%) in the conventional group. After adjusting for age, initial UPCR, initial estimated glomerular filtration rate, the presence of a concomitant membranous lesion in the glomerulus, initial GC dose, use of methylprednisolone pulse therapy, strong immunosuppressants (mycophenolate mofetil, cyclophosphamide or rituximab) and hydroxychloroquine, no significant difference was observed in PRR at 12 months (adjusted risk ratio: 0.92, P = 0.758). Relapse rates and serious adverse events over 2 years of follow-up were also comparable between the groups. CONCLUSION: Rapid GC reduction to ≤7.5 mg/day within 6 months did not compromise renal outcomes or increase relapse in proliferative LN.
引用
- Ohmura K, Shimizu H, Tanaka Y, et al. Impact of glucocorticoid tapering speed on renal outcomes in proliferative lupus nephritis: a multicentre retrospective study. Rheumatology (Oxford). 2025. PMID: 40358545. doi:10.1093/rheumatology/keaf243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。